122 related articles for article (PubMed ID: 3209285)
41. Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma.
Gerber DE; Grossman SA; Batchelor T; Ye X
Cancer Chemother Pharmacol; 2007 May; 59(6):817-23. PubMed ID: 16972068
[TBL] [Abstract][Full Text] [Related]
42. [Controlled ultra-high dosage methotrexate therapy in three patients with metastatic osteosarcoma (author's transl)].
Leber H; Kotz R; Chiari K; Endler T; Gabl F; Krisch K; Salzer-Kuntschik M
Wien Klin Wochenschr; 1981 Apr; 93(7):236-40. PubMed ID: 7020262
[TBL] [Abstract][Full Text] [Related]
43. A specific HPLC assay to determine the pharmacokinetics of methotrexate in patients.
Chen ML; McGuire WP; Lad TE; Chiou WL
Int J Clin Pharmacol Ther Toxicol; 1984 Jan; 22(1):1-6. PubMed ID: 6698654
[TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate after high-dose (33.6 g/m2) methotrexate therapy.
Slørdal L; Kolmannskog S; Prytz PS; Moe PJ; Aarbakke J
Pediatr Hematol Oncol; 1986; 3(2):127-34. PubMed ID: 3153222
[TBL] [Abstract][Full Text] [Related]
45. Population pharmacokinetics of high-dose methotrexate after intravenous administration in Chinese osteosarcoma patients from a single institution.
Zhang W; Zhang Q; Tian X; Zhao H; Lu W; Zhen J; Niu X
Chin Med J (Engl); 2015 Jan; 128(1):111-8. PubMed ID: 25563323
[TBL] [Abstract][Full Text] [Related]
46. Methotrexate removal during haemodialysis in a patient with advanced laryngeal carcinoma.
Thomson AH; Daly M; Knepil J; Harden P; Symonds P
Cancer Chemother Pharmacol; 1996; 38(6):566-70. PubMed ID: 8823500
[TBL] [Abstract][Full Text] [Related]
47. Methotrexate pharmacokinetics following administration of recombinant carboxypeptidase-G2 in rhesus monkeys.
Adamson PC; Balis FM; McCully CL; Godwin KS; Poplack DG
J Clin Oncol; 1992 Aug; 10(8):1359-64. PubMed ID: 1634927
[TBL] [Abstract][Full Text] [Related]
48. Methotrexate megadosage followed by folate rescue. I. A study in clearance patterns.
Salasoo S; Irving MG; Lam-Po0Tang R; O'Gorman-Hughes D; Freedman A
Med J Aust; 1976 May; 1(21):777-9. PubMed ID: 1085404
[TBL] [Abstract][Full Text] [Related]
49. [Tissue concentration of methotrexate in osteosarcoma after high-dose infusion].
Amino K
Nihon Seikeigeka Gakkai Zasshi; 1982 Aug; 56(8):765-76. PubMed ID: 6984057
[TBL] [Abstract][Full Text] [Related]
50. Substitution of l-leucovorin for d,l-leucovorin in the rescue from high-dose methotrexate treatment in patients with osteosarcoma.
Jaffe N; Jorgensen K; Robertson R; George M; Letvak L; Barrett G
Anticancer Drugs; 1993 Oct; 4(5):559-64. PubMed ID: 8292813
[TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetics of high-dose methotrexate in infants aged less than 12 months treated for aggressive brain tumors.
Lucchesi M; Guidi M; Fonte C; Farina S; Fiorini P; Favre C; de Martino M; Sardi I
Cancer Chemother Pharmacol; 2016 Apr; 77(4):857-64. PubMed ID: 26988222
[TBL] [Abstract][Full Text] [Related]
52. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion.
Evans WE; Hutson PR; Stewart CF; Cairnes DA; Bowman WP; Rivera G; Crom WR
Clin Pharmacol Ther; 1983 Mar; 33(3):301-7. PubMed ID: 6600662
[TBL] [Abstract][Full Text] [Related]
53. Methotrexate administered by 6-h and 24-h infusion: a pharmacokinetic comparison.
Borsi JD; Schuler D; Moe PJ
Cancer Chemother Pharmacol; 1988; 22(1):33-5. PubMed ID: 3260832
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics of small doses of methotrexate in patients with psoriasis.
Kamel RS; al-Hakiem MH; Rademaker M; Meyrick Thomas RH; Munro DD
Acta Derm Venereol; 1988; 68(3):267-70. PubMed ID: 2455425
[TBL] [Abstract][Full Text] [Related]
55. The effect of prior cisplatin therapy on the pharmacokinetics of high-dose methotrexate.
Crom WR; Pratt CB; Green AA; Champion JE; Crom DB; Stewart CF; Evans WE
J Clin Oncol; 1984 Jun; 2(6):655-61. PubMed ID: 6539365
[TBL] [Abstract][Full Text] [Related]
56. Delayed High-dose Methotrexate Excretion and Influencing Factors in Osteosarcoma Patients.
Zhang W; Zhang Q; Zheng TT; Zhen JC; Niu XH
Chin Med J (Engl); 2016 Nov; 129(21):2530-2534. PubMed ID: 27779157
[TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetics and toxicity of frequent intermediate dose methotrexate infusions.
Parker RI; Forman EN; Krumm KF; Abeel MJ; Martin HF
Ther Drug Monit; 1986; 8(4):393-9. PubMed ID: 3469802
[TBL] [Abstract][Full Text] [Related]
58. Probenecid inhibition of methotrexate-cerebrospinal fluid pharmacokinetics in dogs.
Ramu A; Fusner JE; Blaschke T; Glaubiger DL
Cancer Treat Rep; 1978 Oct; 62(10):1465-70. PubMed ID: 581360
[TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis.
Tetef ML; Margolin KA; Doroshow JH; Akman S; Leong LA; Morgan RJ; Raschko JW; Slatkin N; Somlo G; Longmate JA; Carroll MI; Newman EM
Cancer Chemother Pharmacol; 2000; 46(1):19-26. PubMed ID: 10912573
[TBL] [Abstract][Full Text] [Related]
60. Phenytoin Michaelis-Menten pharmacokinetics in Saudi patients.
el-Sayed YM; Islam SI
Int J Clin Pharmacol Ther Toxicol; 1989 Apr; 27(4):173-8. PubMed ID: 2714918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
